Testicular cancer is a relatively common malignancy in young males. A surveillance strategy with regular monitoring of tumour makers and cross-sectional imaging of the retroperitoneum is preferred in patients with early stage disease to avoid the toxicity of systemic chemotherapy.
Research Question
The aim of our study was to compare magnetic resonance imaging (MRI) with computed tomography (CT) in the diagnosis of retroperitoneal nodal disease by using evidencebased practice methodology and to determine if MRI can be used as an alternative nonionizing radiation imaging modality for surveillance. Specifically, we wanted to compare the accuracy of MRI against CT, which is the current reference standard, for the detection of enlarged retroperitoneal lymph nodes based on size criteria. By using the McMaster-Oxford ''bottom up'' approach to evidence-based practice [1] , we constructed a focused answerable clinical question: Is MRI comparable with CT in the diagnosis of retroperitoneal metastasis in patients with testicular cancer?
Evidence
Based on the research question and by using the PICO (Patient, Intervention, Comparison, and Outcome) format [2] , a literature search strategy was formatted by using relevant MeSH (medical subject heading) ( Figure 1 ). The evidence-based pyramid as previously described by Haynes [3] broadly divides available literature into primary and secondary literature. A search was performed in a top-down approach through this evidence pyramid by using the MeSH terms mentioned above. The secondary literature search included information systems, the Cochrane Collaboration, Trip Database, SUMSearch, and guidelines. Subsequently, a search of the primary literature by using PubMed was performed. Expert consensus guidelines, narrative reviews, editorials, and case reports were excluded. The following limits were also applied: English language, human, and published since 2001. Based on these criteria, the initial primary literature search yielded 86 abstracts. When the criteria above were applied and when filtered for relevance to the research question, 3 relevant articles were identified [4e 6]. A further search of the secondary literature and of the reference lists of these articles yielded no additional results.
The best current evidence is derived from a prospective study [6] , categorized as level 1b evidence according to the Oxford Centre for Evidence-based Medicine criteria. This study was reviewed by using explicit evidence-based medicine criteria, and the methodology was found to be valid and satisfactory [7] . In this study, Sohaib et al [6] prospectively evaluated 52 men with testicular germ cell tumours (GCT) who underwent imaging with both multidetector CT and 1.5T MRI. Patients admitted to the study included all men with testicular GCT who were referred for imaging and excluded patients who could not be scheduled for both a CT and MRI examination within a 6-week period. The aim of the study was to assess how MRI performed in its relative sensitivity for the detection of enlarged retroperitoneal nodes as seen on CT, which is the current reference standard. Positive lymph nodes were defined by using the size criteria of 1 cm maximum short-axis diameter. The researchers also performed a secondary analysis that compared both modalities against a reference standard of combined MRI and CT findings to account for findings that may potentially be better detected on MRI. Techniques for both modalities were described in detail, which allowed replication in other facilities and MRI acquisitions were based on noncontrast axial and coronal T1-and T2-weighted fast spin-echo sequences.
Three radiologists of varying experience read the studies independently and on separate occasions more than 4 weeks apart and were blinded to clinical details and other imaging findings. Their results showed that MRI was comparable with CT in the detection of any retroperitoneal disease when read by readers with more than 10 years of experience, reporting a sensitivity of 97% (95% confidence interval [CI], 80%-100%) when compared with CT as a reference standard. When read by a trainee radiologist with 1 year of experience, the sensitivity was 80% (95% CI, 61%-92%). Compared with a pooled reference standard of both MRI and CT findings, similar sensitivities were also seen for both modalities when read by experienced readers ( Table 1) .
The next best level of evidence is a level 3a systematic review (SR), which incorporated 2 studies without a consistently applied reference standard [4] . This SR was published before the prospective study by Sohaib et al [6] and highlighted the huge gaps of evidence that compared MRI and CT at that time. The only other available comparison was from a pilot prospective study by Harisinghani et al [5] , which compared the sensitivity of lymphotropic nanoparticle-enhanced MRI with nodal disease detection by size criteria by using unenhanced MRI and CT. When compared with pathologic evaluation as a reference standard, both unenhanced MRI and CT were concluded to have comparable sensitivities (Table 1 ). However, this study was not designed to compare MRI and CT directly, and no information was provided in the methodology regarding CT acquisition techniques and comparison protocols. Thus, the validity of this conclusion is poor on the basis of the presented information.
Clinical Applicability and Comments
The incidence of testicular cancer has doubled over the past 20-30 years [8e10]. Most testicular tumours are GCTs that consist of seminomas (40%) and nonseminomas (60%), with excellent cure rates in excess of 95% for early stage disease [8, 10] . In patients with stage 1 testicular GCT, surveillance with regular follow-up of tumour makers and imaging to detect disease relapse is preferred. Because the pattern of relapse is predictable, imaging is focused on the retroperitoneum, with CT evaluation performed at regular intervals. A standard surveillance program in Europe involves 7 abdominal CTs over a 5-year period; however, significant regional variations exist with up to 13 or more scans performed in some centres, with an approximate cumulative dose of up to 260 mSv [11] . Whereas the surveillance strategy avoids toxicity of adjuvant systemic therapy, the cumulative exposure to ionizing radiation in this young population merits equal consideration. The lifetime risk of radiation-induced secondary malignancy from CT surveillance has been estimated at 1.2%-1.9%, with a higher risk at a younger age at presentation [12] .
There is good evidence to show that MRI is comparable with CT in the detection of retroperitoneal nodal disease in patients with testicular GCT when read by experienced radiologists. The technique is based around basic MRI sequences, which are well described by the researchers and may be easily adopted by most centres. The limitation of the study population to subjects with testicular GCTs means that results may not be applicable to all but should apply to a large majority of patients with testicular cancer. Barriers to a change in practice include access to MRI services and waiting lists, which may be less of a problem with CT. Nevertheless, the current available evidence suggests that MRI may be used as an alternative imaging modality to CT in surveillance and has the potential to markedly reduce ionizing radiation exposure in this young patient group. 
